全文获取类型
收费全文 | 2918877篇 |
免费 | 200334篇 |
国内免费 | 7860篇 |
专业分类
耳鼻咽喉 | 38897篇 |
儿科学 | 95854篇 |
妇产科学 | 79635篇 |
基础医学 | 420996篇 |
口腔科学 | 78000篇 |
临床医学 | 265913篇 |
内科学 | 571827篇 |
皮肤病学 | 69774篇 |
神经病学 | 233973篇 |
特种医学 | 111831篇 |
外国民族医学 | 774篇 |
外科学 | 435390篇 |
综合类 | 55755篇 |
现状与发展 | 6篇 |
一般理论 | 1043篇 |
预防医学 | 221856篇 |
眼科学 | 64908篇 |
药学 | 213808篇 |
9篇 | |
中国医学 | 5961篇 |
肿瘤学 | 160861篇 |
出版年
2019年 | 22798篇 |
2018年 | 32498篇 |
2017年 | 24904篇 |
2016年 | 28952篇 |
2015年 | 32524篇 |
2014年 | 44535篇 |
2013年 | 66626篇 |
2012年 | 89386篇 |
2011年 | 94990篇 |
2010年 | 57095篇 |
2009年 | 54327篇 |
2008年 | 88458篇 |
2007年 | 94331篇 |
2006年 | 95777篇 |
2005年 | 91596篇 |
2004年 | 88275篇 |
2003年 | 85405篇 |
2002年 | 82392篇 |
2001年 | 139982篇 |
2000年 | 143242篇 |
1999年 | 120585篇 |
1998年 | 34346篇 |
1997年 | 30422篇 |
1996年 | 30703篇 |
1995年 | 29665篇 |
1994年 | 27181篇 |
1993年 | 25589篇 |
1992年 | 93394篇 |
1991年 | 91036篇 |
1990年 | 88382篇 |
1989年 | 85585篇 |
1988年 | 78386篇 |
1987年 | 76851篇 |
1986年 | 71889篇 |
1985年 | 68730篇 |
1984年 | 51029篇 |
1983年 | 43132篇 |
1982年 | 25148篇 |
1981年 | 22521篇 |
1979年 | 45097篇 |
1978年 | 31823篇 |
1977年 | 26801篇 |
1976年 | 25347篇 |
1975年 | 27462篇 |
1974年 | 32080篇 |
1973年 | 30493篇 |
1972年 | 28510篇 |
1971年 | 26582篇 |
1970年 | 24557篇 |
1969年 | 23547篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
141.
Thomas W. McDade Alexander V. Georgiev Christopher W. Kuzawa 《Evolution, Medicine, and Public Health》2016,2016(1):1-16
Immune defenses provide resistance against infectious disease that is critical to survival. But immune defenses are costly, and limited resources allocated to immunity are not available for other physiological or developmental processes. We propose a framework for explaining variation in patterns of investment in two important subsystems of anti-pathogen defense: innate (non-specific) and acquired (specific) immunity. The developmental costs of acquired immunity are high, but the costs of maintenance and activation are relatively low. Innate immunity imposes lower upfront developmental costs, but higher operating costs. Innate defenses are mobilized quickly and are effective against novel pathogens. Acquired responses are less effective against novel exposures, but more effective against secondary exposures due to immunological memory. Based on their distinct profiles of costs and effectiveness, we propose that the balance of investment in innate versus acquired immunity is variable, and that this balance is optimized in response to local ecological conditions early in development. Nutritional abundance, high pathogen exposure and low signals of extrinsic mortality risk during sensitive periods of immune development should all favor relatively higher levels of investment in acquired immunity. Undernutrition, low pathogen exposure, and high mortality risk should favor innate immune defenses. The hypothesis provides a framework for organizing prior empirical research on the impact of developmental environments on innate and acquired immunity, and suggests promising directions for future research in human ecological immunology. 相似文献
142.
143.
More than just crushing: a prospective pre‐post intervention study to reduce drug preparation errors in patients with feeding tubes 下载免费PDF全文
144.
145.
146.
147.
148.
149.
150.
Archie L. Overmann DesRaj M. Clark Panagiotis Tsagkozis Rikard Wedin Jonathan A. Forsberg 《Journal of orthopaedic research》2020,38(10):2149-2156
Treatment decisions in patients with metastatic bone disease rely on accurate survival estimation. We developed the original PATHFx models using expensive, proprietary software and now seek to provide a more cost-effective solution. Using open-source machine learning software to create PATHFx version 2.0, we asked whether PATHFx 2.0 could be created using open-source methods and externally validated in two unique patient populations. The training set of a well-characterized, database records of 189 patients and the bnlearn package within R Version 3.5.1 (R Foundation for Statistical Computing), was used to establish a series of Bayesian belief network models designed to predict survival at 1, 3, 6, 12, 18, and 24 months. Each was externally validated in both a Scandinavian (n = 815 patients) and a Japanese (n = 261 patients) data set. Brier scores and receiver operating characteristic curves to assessed discriminatory ability. Decision curve analysis (DCA) evaluated whether models should be used clinically. DCA showed that the model should be used clinically at all time points in the Scandinavian data set. For the 1-month time point, DCA of the Japanese data set suggested to expect better outcomes assuming all patients will survive greater than 1 month. Brier scores for each curve demonstrate that the models are accurate at each time point. Statement of Clinical Significance: we successfully transitioned to PATHFx 2.0 using open-source software and externally validated it in two unique patient populations, which can be used as a cost-effective option to guide surgical decisions in patients with metastatic bone disease. 相似文献